Sensei Biotherapeutics, Inc. (SNSE) · 6+ Years of Financial Ratios

Profitability	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -
Return on Assets (%)	- -	-1,091.62	-177.52	-42.13	-35.78	-35.38
Return on Capital (%)	- -	- -	- -	- -	- -	- -
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -
Gross Margin (%)	- -	- -	- -	- -	- -	- -
EBITDA Margin (%)	- -	- -	- -	- -	- -	- -
Operating Margin (%)	- -	- -	- -	- -	- -	- -
Incremental Operating Margin (%)	- -	- -	- -	- -	- -	- -
Pretax Margin (%)	- -	- -	- -	- -	- -	- -
Profit Margin (%)	- -	- -	- -	- -	- -	- -
Net Income to Common Margin (%)	- -	- -	- -	- -	- -	- -
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -
Dvd Payout Ratio (%)	22.59	18.52	0.51	- -	- -	- -
Sustainable Growth Rate (%)	- -	- -	- -	- -	- -	- -

Credit	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Total Debt	5	16	1	2	8	6
ST Debt	1	16	- -	1	2	2
LT Debt	4	- -	1	2	6	4
Total Debt/EBITDA	-0.37	-1.3	-0.04	-0.06	-0.16	-0.17
Net Debt/EBITDA	-0.32	-1.28	0.87	0.19	0.36	0.36
Total Debt/EBIT	-0.37	-1.29	-0.04	-0.06	-0.16	-0.17
Net Debt/EBIT	-0.32	-1.27	0.86	0.19	0.35	0.35
EBITDA to Interest Expense	-38.83	-5.48	-10.96	-54.92	-223.02	-248.01
EBITDA-CapEx/Interest Expense	-38.92	-5.5	-11.67	-57.94	-224.48	-249.26
EBIT to Interest Expense	-38.96	-5.51	-11.08	-55.94	-229.17	-257.39
Interest Expense	- -	2	2	1	- -	- -
Common Equity/Total Assets	-4,084.97	-7,585.21	-524.6	-97.38	-167.09	-311.79
Long-Term Debt/Equity (%)	- -	- -	- -	1.14	5.71	5.81
Long-Term Debt/Capital (%)	-17.4	- -	-0.58	-1.14	-3.11	-1.67
Long-Term Debt/Total Assets (%)	218.92	- -	3.05	1.09	4.99	5.07
Total Debt/Equity (%)	-8.87	-23.38	-1.21	1.61	7.77	9.57
Total Debt/Capital (%)	-20.39	-55.92	-0.61	-1.6	-4.23	-2.75
Total Debt/Total Assets (%)	256.54	1,319.23	3.2	1.54	6.79	8.35
Net Debt to Equity	-7.65	-23.02	28.4	-4.89	-17.21	-20.05
Net Debt/Capital (%)	-17.1	-54.57	12.49	4.65	8.57	5.45
EBITDA	-13	-12	-19	-37	-49	-36
EBITDA-CapEx	-13	-12	-20	-39	-49	-36
Operating Income (Loss)	-13	-12	-19	-37	-50	-37

Liquidity	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Cash Ratio	0.25	0.01	3.44	30.19	11.82	11.65
Current Ratio	0.48	0.02	4.16	30.38	11.98	11.92
Quick Ratio	0.25	0.01	3.44	30.19	11.82	11.65
CFO/Avg Current Liab	- -	-0.7	-1.33	-6.23	-5.59	-4.35
Common Equity/Total Assets	-4,084.97	-7,585.21	-524.6	-97.38	-167.09	-311.79
Long-Term Debt/Equity (%)	- -	- -	- -	1.14	5.71	5.81
Long-Term Debt/Capital (%)	-17.4	- -	-0.58	-1.14	-3.11	-1.67
Long-Term Debt/Total Assets (%)	218.92	- -	3.05	1.09	4.99	5.07
Total Debt/Equity (%)	-8.87	-23.38	-1.21	1.61	7.77	9.57
Total Debt/Capital (%)	-20.39	-55.92	-0.61	-1.6	-4.23	-2.75
Total Debt/Total Assets (%)	256.54	1,319.23	3.2	1.54	6.79	8.35
CFO/Total Liabilities	-18.64	-12.27	-22.74	-450.82	-260.73	-337.83
CFO/CapEx	-332.68	-161.72	-14.68	-14.94	-121.58	-177.91
Altman's Z-Score	-80.81	-160.83	-9.37	14	-0.95	-3.84

Working Capital	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Accounts Receivable Turnover	- -	- -	- -	- -	- -	- -
Days Sales Outstanding	- -	- -	- -	- -	- -	- -
Inventory Turnover	- -	- -	- -	- -	- -	- -
Days Inventory Outstanding	- -	- -	- -	- -	- -	- -
Accounts Payable Turnover	- -	- -	- -	- -	- -	- -
Accounts Payable Turnover Days	- -	- -	- -	- -	- -	- -
Cash Conversion Cycle	- -	- -	- -	- -	- -	- -
Inventory to Cash Days	- -	- -	- -	- -	- -	- -
Inventories	- -	- -	- -	- -	- -	- -
Raw Materials	- -	- -	- -	- -	- -	- -
Work In Process	- -	- -	- -	- -	- -	- -
Finished Goods	- -	- -	- -	- -	- -	- -
Other Inventory	- -	- -	- -	- -	- -	- -

Enterprise Value	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Market Capitalization	- -	- -	- -	168	44	19
- Cash & Cash Equivalents	1	- -	17	7	18	13
+ Preferred Equity and Hybrid Capital	48	48	- -	- -	- -	- -
+ Minority/Non Controlling Interest	- -	- -	- -	- -	- -	- -
+ Total Debt	5	16	1	2	8	6
Enterprise Value	52	63	-16	23	-55	-41
Total Capital	-23	-29	-112	-147	-190	-226
Total Debt/Capital (%)	-20.39	-55.92	-0.61	-1.6	-4.23	-2.75
Total Debt / EV	0.09	0.25	-0.04	0.1	-0.15	-0.15
EV/Sales	- -	- -	- -	- -	- -	- -
EV/EBITDA	- -	- -	- -	- -	- -	- -
EV/EBIT	- -	- -	- -	- -	- -	- -
EV/Cash Flow to Firm	- -	- -	- -	- -	- -	- -
EV/Free Cash Flow to Firm	- -	- -	- -	- -	- -	- -
Diluted Market Cap	- -	- -	- -	152	44	21
Diluted Enterprise Value	52	63	-16	148	34	14
EV per Share	75.38	5.14	- -	0.75	- -	- -
TTM Sales	- -	- -	- -	- -	- -	- -
TTM EBITDA	-13	-12	-19	-37	-49	-36
TTM Operating Income	-13	-12	-19	-37	-50	-37
TTM Cash Flow to Firm	-10	-6	-16	-30	-39	-32
TTM Free Cash Flow to Firm	-10	-6	-15	-28	-38	-32

Multiples	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Price/Earnings	- -	- -	- -	- -	- -	- -
Price/Earnings Average	- -	- -	- -	-8.25	-1.48	-0.96
Price/Earnings High	- -	- -	- -	-16	-3.59	-1.33
Price/Earnings Low	- -	- -	- -	-3.65	-0.84	-0.43
Price/Book Value	- -	- -	- -	-1.13	-0.22	-0.08
Price/Book Value Average	- -	- -	- -	-2.25	-0.36	-0.13
Price/Book Value High	- -	- -	- -	-4.36	-0.88	-0.17
Price/Book Value Low	- -	- -	- -	-0.99	-0.21	-0.06
Price/Tangible Book Value	- -	- -	- -	1.15	0.43	0.29
Price/Tangible Book Value Average	- -	- -	- -	2.29	0.69	0.45
Price/Tangible Book Value High	- -	- -	- -	4.44	1.69	0.62
Price/Tangible Book Value Low	- -	- -	- -	1.01	0.4	0.2
Price/Sales	- -	- -	- -	- -	- -	- -
Price/Sales Average	- -	- -	- -	- -	- -	- -
Price/Sales High	- -	- -	- -	- -	- -	- -
Price/Sales Low	- -	- -	- -	- -	- -	- -
Price/Cash Flow	- -	- -	- -	-5.04	-1.13	-0.65
Price/Cash Flow Average	- -	- -	- -	-10.03	-1.84	-1.03
Price/Cash Flow High	- -	- -	- -	-19.46	-4.47	-1.41
Price/Cash Flow Low	- -	- -	- -	-4.44	-1.05	-0.46
Price/Free Cash Flow	- -	- -	- -	-5.4	-1.14	-0.65
Price/Free Cash Flow Average	- -	- -	- -	-10.75	-1.85	-1.03
Price/Free Cash Flow High	- -	- -	- -	-20.86	-4.51	-1.42
Price/Free Cash Flow Low	- -	- -	- -	-4.76	-1.06	-0.47
EV/Sales	- -	- -	- -	- -	- -	- -
EV/Sales Average	- -	- -	- -	- -	- -	- -
EV/Sales High	- -	- -	- -	- -	- -	- -
EV/Sales Low	- -	- -	- -	- -	- -	- -
EV/EBITDA	- -	- -	- -	- -	- -	- -
EV/EBITDA Average	-4.07	-5.12	0.86	-8.98	-1.27	-0.63
EV/EBITDA High	-4.07	-5.12	0.86	-17.55	-3.38	-0.94
EV/EBITDA Low	-4.07	-5.12	0.86	-3.9	-0.64	-0.18
EV/EBIT	- -	- -	- -	- -	- -	- -
EV/EBIT Average	-4.05	-5.09	0.85	-8.81	-1.24	-0.61
EV/EBIT High	-4.05	-5.09	0.85	-17.23	-3.29	-0.91
EV/EBIT Low	-4.05	-5.09	0.85	-3.83	-0.62	-0.17
Last Price	- -	- -	- -	5.5	1.44	0.74
High Price	- -	- -	- -	21.25	5.68	1.62
Low Price	- -	- -	- -	4.85	1.33	0.53
Enterprise Value	52	63	-16	23	-55	-41
Enterprise Value Average	52	63	-16	330	62	23
Enterprise Value High	52	63	-16	646	165	34
Enterprise Value Low	52	63	-16	144	31	6

Per Share Data Items	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Shares Outstanding	1	12	30	31	31	25
Diluted Weighted Avg Shares	1	12	30	28	31	28
Basic Weighted Avg Shares	1	12	30	28	31	28
Revenue per Share	- -	- -	- -	- -	- -	- -
EBITDA per Share	-18.53	-1	-0.63	-1.33	-1.59	-1.28
Operating Income per Share	-18.6	-1.01	-0.63	-1.35	-1.63	-1.33
Basic EPS, GAAP	-24.59	-1.67	-0.68	-1.33	-1.58	-1.22
Basic EPS from Cont Ops	-19.04	-1.36	-0.68	-1.33	-1.58	-1.22
Diluted EPS, GAAP	-24.59	-1.67	-0.68	-1.33	-1.58	-1.22
Diluted EPS from Cont Ops	-19.04	-1.36	-0.68	-1.33	-1.58	-1.22
Dividend per Share	- -	- -	- -	- -	- -	- -
Cash Flow per Share	-15.06	-0.7	-0.6	-1.09	-1.27	-1.15
Free Cash Flow per Basic Share	-15.1	-0.7	-0.64	-1.17	-1.28	-1.15
Cash & Equivalents per Share	0.95	0.02	0.56	4.82	3.48	2.63
Book Value per Share	-110.32	-7.49	-3.8	-4.87	-6.43	-9.26
Tangible Book Value per Share	-147.48	-9.43	-1.91	4.79	3.36	2.59

Sensei Biotherapeutics, Inc.

SNSE US

0.63